Axxin supported by ZiP Diagnostics have been awarded a contract with the Geneva-based Foundation for Innovative New Diagnostics (FIND) to develop and commercialise a CT-NG (chlamydia and gonorrhoea) point-of-care test system.
​
The Phase 1 proof-of-concept work required rigorous pre-clinical testing including extensive sensitivity and specific testing. The testing was conducted in collaboration with the Victorian Infectious Diseases Reference Laboratory (VIDRL). The success of this work has led to awarding of a phase 2 diagnostic contract.